戻る Agenda
Session 16: Group Exercise II: Monitoring Development of a Novel Anti-Psychotic
Session Chair(s)
William Gregory, PhD
Senior Director, Safety and Risk Management
Pfizer Inc, United States
A clinical monitoring scenario involving pharmacokinetics of a novel anti-psychotic product will be presented for discussion in small groups. All groups will share their considerations for actions and next steps with all participants.